The state of Florida currently has 35 active clinical trials seeking participants for Asthma research studies. These trials are conducted in various cities, including Miami, Tampa, Jacksonville and Orlando.
Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.
NCT06473779
Recruiting
The objective of this study is to assess the potential for tezepelumab-treated patients (subcutaneous administration) to reduce maintenance therapy without loss of asthma control in adolescent and adults with severe asthma.. Study details include: 1. The study duration will be up to 72 weeks. 2. The treatment duration will be up to 68 weeks. 3. The visit frequency will be once every 4 weeks (Q4W).
Gender:
ALL
Ages:
Between 12 years and 80 years
Trial Updated:
06/16/2025
Locations: Research Site, Miami, Florida
Conditions: Severe Asthma
Register for Updates
A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations
NCT06529419
Recruiting
A dose range-finding study to assess the efficacy and safety of multiple dose levels of AZD8630 administered via a dry powder inhaler in adults with uncontrolled asthma at risk of exacerbations, receiving medium -to -high dose inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/16/2025
Locations: Research Site, DeBary, Florida +6 locations
Conditions: Asthma
Register for Updates
Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics
NCT03953300
Recruiting
The purpose of the study is to evaluate effect of benralizumab on structural and lung function changes in severe eosinophilic asthmatics. Changes will be assessed over 48 week treatment period in patients with persistent symptoms despite standard therapy of inhaled corticosteroids (ICS) plus long acting B2-agonist (LABA) with or without additional controller medication. Patients who complete treatment will enter 4 weeks follow-up period.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/13/2025
Locations: Research Site, Jacksonville, Florida +2 locations
Conditions: Asthma
Register for Updates
Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA
NCT06020014
Recruiting
This is a Phase 2a, multicentre, randomised, placebo-controlled, double-blind, parallel-group study to evaluate the efficacy, safety and PK of AZD4604 administered BID using a dry-powder inhaler at one dose level over a 12-week Treatment period in adult participants with uncontrolled moderate-to-severe asthma.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/11/2025
Locations: Research Site, Lakeland, Florida +3 locations
Conditions: Asthma
Register for Updates
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations
NCT06052267
Recruiting
The primary objective of the study is to assess the efficacy of high dose and low dose fluticasone propionate (Fp)/albuterol sulfate (ABS) integrated electronic module multidose dry powder inhaler (eMDPI) compared to ABS eMDPI in decreasing severe clinical asthma exacerbation (CAEs). Secondary Objectives: To evaluate the efficacy of Fp/ABS compared to ABS and the effect on systemic corticosteroid (SCS) exposure To evaluate the safety and tolerability of Fp/A BS The duration for each particip... Read More
Gender:
ALL
Ages:
4 years and above
Trial Updated:
06/11/2025
Locations: Teva Investigational Site 15660, Aventura, Florida +41 locations
Conditions: Asthma
Register for Updates
Asthma and Technology in Emerging African American Adults
NCT05445583
Recruiting
The purpose of the ATHENA Project is to test a mobile health intervention to help African American young adults better manage their asthma. The program has four components: 1) a web-based, mobile asthma program delivered to participants' mobile device, 2) meetings with an asthma nurse via video conference, 3) text messaging, and 4) physical activity tracking. Participants will be randomly assigned to one or more of these components to better meet the needs of young adults with asthma.
Gender:
ALL
Ages:
Between 18 years and 30 years
Trial Updated:
06/10/2025
Locations: Florida State University, Tallahassee, Florida
Conditions: Asthma
Register for Updates
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.
NCT05763121
Recruiting
This study will assess the efficacy and safety of dexpramipexole as an adjunctive oral therapy in participants with inadequately controlled asthma with an eosinophilic phenotype and a history of asthma exacerbations.
Gender:
ALL
Ages:
Between 12 years and 99 years
Trial Updated:
06/10/2025
Locations: Research Site 20001-048, Aventura, Florida +19 locations
Conditions: Eosinophilic Asthma, Asthma; Eosinophilic, Asthma
Register for Updates
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)
NCT05813288
Recruiting
The objective of this clinical study is to investigate the safety, tolerability, and efficacy of dexpramipexole in participants with inadequately controlled severe eosinophilic asthma.
Gender:
ALL
Ages:
Between 12 years and 99 years
Trial Updated:
06/10/2025
Locations: Research Site 30001-291, Jacksonville, Florida +13 locations
Conditions: Eosinophilic Asthma, Asthma; Eosinophilic, Asthma
Register for Updates
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
NCT05097287
Recruiting
This is an interventional, randomized, parallel group, treatment, Phase 3b/4, double blind, 2-arm study to assess the effect of dupilumab compared to standard of care therapy on preventing or slowing the rate of lung function decline in adult patients with uncontrolled moderate to severe asthma. The estimated duration is 4±1 weeks of screening and run-in period, followed by a 3-year double blinded treatment period. There will be a post-treatment follow-up (FU) period up to 12 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/09/2025
Locations: Central Florida Pulmonary Group - Altamonte Springs- Site Number : 8400035, Altamonte Springs, Florida +10 locations
Conditions: Asthma
Register for Updates
A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)
NCT06966479
Recruiting
The primary purpose of this study is to evaluate the long-term safety and efficacy of verekitug (UPB-101) in participants who complete the VALIANT study (NCT06196879).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: Edward Jenner Research Group, LLC, Plantation, Florida +1 locations
Conditions: Severe Asthma
Register for Updates
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
NCT05757102
Recruiting
The primary purpose of this study is to evaluate the effects of Fluticasone Furoate (FF)/ Umeclidinium (UMEC)/ Vilanterol (VI) on lung function compared with FF/VI after 24 weeks of treatment.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
06/04/2025
Locations: GSK Investigational Site, Aventura, Florida +3 locations
Conditions: Asthma
Register for Updates
Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma
NCT05251259
Recruiting
This is a randomised, placebo-controlled, double-blind study to assess the efficacy and safety of Atuliflapon administered once daily over a 12-week treatment period to adult participants with moderate to severe uncontrolled asthma.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/03/2025
Locations: Research Site, Clearwater, Florida +25 locations
Conditions: Asthma
Register for Updates